CD93 and neoplasm: Blockade of CD93 with monoclonal antibodies against CD93 (anti-CD93) markedly inhibited lung tumor growth by inducing CCL21 secretion from pMCs and preventing tumor angiogenesis, thus showing better efficacy than blocking vascular endothelial growth factor receptor (VEGFR).